|
|
|
| Study on the mechanism of “seaweed-tangle” in the treatment of goiter based on network pharmacology |
| YANG Fuchen ZHANG Shichao |
| Department of Orthopeadic Surgery, Shenben Hospital Affiliated to Liaoning University of Traditional Chinese Medicine, Liaoning Province, Benxi 110032, China |
|
|
|
Abstract Objective To explore the material basis and action mechanism of seaweed and tangle in the treatment of goiter through network pharmacology research methods. Methods The main active components of seaweed and tangle were searched in pharmacology database of traditional Chinese medicine system pharmacology database and analysis platform (TCMSP), and the targets of action were predicted. The disease targets related to goiter were searched by DisGeNET, OMIM and GeneCards databases, and the intersection with traditional Chinese medicine targets was obtained to screen the common targets. The protein protein interaction (PPI) network was drawn based on String platform, and the core targets were selected by topology analysis of Cytoscape software. The biological function of GO-BP and the enrichment of KEGG pathway were analyzed by metascape software. Results According to database analysis, seaweed contained four active compounds and 225 targets, tangle contained six active compounds and 145 action targets. After taking the intersection with the goiter target, a total of 70 targets were obtained. GO-BP bioaccumulation and KEGG pathway analysis showed that seaweed and tangle could regulate cell protein localization, G1/S transition of mitotic cell cycle, synthesis of nitrogen compounds, response of hormone stimulation and acidic chemicals, MAPK cascade and other biological processes, as well as p53 signal pathway, adhesive plaque, ErbB signal pathway, VEGF signal pathway and Jak-STAT signal pathway, etc. Conclusion This study explores the material basis and action mechanism of seaweed and tangle in the treatment of goiter from multiple perspectives such as compounds, targets, pathways, and provides a new scientific basis for future clinical trials and basic experimental research.
|
|
|
|
|
|
[1] Shan ZY，Chen LL，Lian XL，et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China：a cross-sectional study in 10 cities [J]. Thyroid，2016，26（8）：1125-1130.
[2] 汪昂.本草备要[M].北京：人民卫生出版社，2005：33．
[3] 孙远，徐禄玉，黄桃，等.基于数据挖掘分析明清医家治疗瘿病用药规律[J].河南中医，2020，40（2）：258-261.
[4] 段志园，刘庆阳，高天舒.中医古籍中治疗石瘿的主要用药规律及聚类分析[J].江西中医药，2019，50（3）：8-10.
[5] 孙志东.海藻昆布方加减治疗甲状腺结节临床观察[C]//中国中西医结合学会.5TH全国中西医结合内分泌代谢病学术大会暨糖尿病论坛论文集，2012：574-575.
[6] Zhang YQ，Mao X，Guo QY，et al. Network pharmacology-based approaches capture essence of Chinese herbal med-icines [J]. Chin Herb Med，2016，8（2）：107-116.
[7] 韩彦琪，孟凡翠，许浚，等.基于网络药理学方法的元胡止痛滴丸治疗原发性痛经的配伍合理性研究[J].中草药，2017，48（3）：526-532.
[8] Ru J，Li P，Wang J，et al. TCMSP：a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform，2014，6（1）：1-6.
[9] 邹岳.外科真诠[M].北京：中医古籍出版社，1995：15．
[10] Rengasamy KR，Mahomoodally MF，Aumeeruddy MZ，et al. Bioactive compounds in seaweeds：an overview of their biological properties and safety [J]. Food Chem Toxicol，2020，135：111013.
[11] 张晓萍，张文，戚鹏飞，等.海藻及其混伪品中17种氨基酸的含量测定[J].中国药房，2020，31（4）：468-472.
[12] 杜成智，侯小涛，郝二伟，等.植物类海洋中药化学成分及药理作用研究进展[J].广西科学，2019，26（5）：466-476.
[13] Lu J，You L，Lin Z，et al. The antioxidant capacity of polysaccharide fromLaminaria japonica by citric acid extraction [J]. Int J Food Sci Technol，2013，48（7）：1352-1358．
[14] 赵文杰，陈丽红，李晓霞.昆布多糖对巨噬细胞识别、吞噬烟曲霉功能的影响[J].中医药通报，2019，18（5）：61-63.
[15] Mohibbullah M，Bashir KMI，Kim SK，et al. Protective effects of a mixed plant extracts derived from Astragalus membranaceus and Laminaria japonica on PTU-induced hypothyroidism and liver damages [J]. J Food Biochem，2019，43（7）：e12853.
[16] 曾祥丽，丁安伟.昆布的药理研究进展[J].中医药通报，2007，6（4）：63-66.
[17] 沈育锋，胡海.P53在结节性甲状腺肿合并甲状腺癌中的表达及其相关性研究[J].实用癌症杂志，2016，31（10）：1590-1592.
[18] Tamburrino A，Molinolo AA，Salerno P，et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymphnode metastases [J]. Clin Cancer Res，2012，18（13）：3532-3540.
[19] Saji M，Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors [J]. Mol Cell Endocrinol，2010，321（1）：20-28.
[20] 颜培培，赵晓娟，王铜浩.APP/PS1转基因小鼠的甲状腺功能变化[J].中国医科大学学报，2011，40（8）：703-705.
[21] Ruffolo C，Scarpa M，Bassi N，et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis [J]. J Clin Endocrinol Metabol，1998，83（11）：3908-3912.
[22] Shibuya M. VEGF-VEGFR signals in health and disease [J]. Biomol Ther（Seoul），2014，22（1）：1-9.
[23] Nagura S，Katoh R，Miyagi E，et al. Expression of vascular endothelial growth factor（VEGF）and VEGF receptor-1（Flt-1）in Graves disease possibly correlated with increased vascular density [J]. Human Pathol，2001，32（1）：10-17.
[24] Milani AT，Khadem-Ansari MH，Rasmi Y. Effects of thyroxine on adhesion molecules and proinflammatory cytokines secretion on human umbilical vein endothelial cells [J]. Res Pharm Sci，2019，14（3）：237-246.
[25] 谭文婷，李琳，唐芬，等.硫化氢通过抑制STAT1通路改善高甲状腺素导致的大鼠心肌纤维化[J].临床心血管病杂志，2017，33（8）：790-793.
[26] Campo Verde Arboccó F，Persia FA，Hapon MB，et al. Hypothyroidism decreases JAK/STAT signaling pathway in lactating rat mammary gland [J]. Mol Cell Endocrinol，2017，450：14-23. |
|
|
|
